Table 1. Clinical, histopathological, and molecular features of adrenal adenoma, IGF2-low carcinoma, and IGF2-high carcinoma.
| Adenomas (n = 87) | CS IGF2-low (n = 10) | CS IGF2-high (n = 43) | p-value (CS IGF2-low vs CS IGF2-high) | |
| Sex (Men/Women) | 8/79 | 2/8 | 10/33 | 1a |
| Age at diagnosis (median (range), year) | 48 (22–76) | 57.5 (26–81) | 45 (15–79) | 0.17b |
| Weight (median (range), g) | 16 (5–240) | 134.5 (40–551) | 249 (50–2700) | 0.09 b |
| Size (median (range), cm) | 3.5 (2–10) | 9 (4–16) | 11 (5–24) | 0.31 b |
| Weiss score (median (range)) | 0 (0–2) | 6 (3–9) | 6 (3–8) | 0.7 b |
| ENSAT score (median (range)) | 1 (1–2) | 2 (1–4) | 2 (1–4) | 0.52 b |
| Secretion (yes/no) | 53/34 | 10/0 | 34/9 | 0.18 a |
| Ki67 (median (range), positive cells/1000) | 0 (0–18) | 14 (0–118) | 8.5 (0–269) | 0.85 b |
| Metastatic (yes/no) | 0/87 | 5/5 | 22/20 | 1 a |
| Treatment (surgery/surgery + mitotane) | 83/4 | 4/5 | 14/25 | 0.7 a |
| 17p13 LOH (yes/no) | 0/22 | 7/3 | 26/5 | 0.38 a |
| DLGAP5 (DLG7)-PINK1 elevated risk of recurrence (yes/no) | 0/87 | 8/2 | 26/15 | 0.46 a |
| BUB1B-PINK1 poor prognosis (yes/no) | 0/87 | 7/3 | 24/18 | 0.72 a |
| TP53 mutation (yes/no) | NA | 3/4 | 5/33 | 0.09 a * |
| Abnormal TP53 IHC (yes/no) | NA | 4/4 | 8/27 | 0.19 a |
| CTNNB1 mutation (yes/no) | NA | 2/6 | 6/32 | 0.61 a |
| Abnormal CTNNB1 IHC (yes/no) | NA | 4/4 | 8/27 | 0.19 a |
These various characteristics were determined as detailed in Material and Methods. P-values were calculated with the Fisher's exact test (a) or Wilcoxon test (b) and show no significant differences between IGF2-high and IGF2-low ACC. When numbers do not add up to 10 for IGF2-low and 43 for IGF2-high, this indicates that data are not available for all patients.